Lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells

Clinical Cancer Research

Volumn 14, Issue 14, 2008, Pages 4650-4657

  Wu, Lei ^a   Adams, Mary ^a   Carter, Troy ^a   Chen, Roger ^a   Muller, George ^a   Stirling, David ^a   Schafer, Peter ^a   Bartlett, J Blake ^a  

^a CELGENE CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; FLUDARABINE; GAMMA INTERFERON; GRANZYME B; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1 ANTIBODY; INTERLEUKIN 12; INTERLEUKIN 2; LENALIDOMIDE; RITUXIMAB; THALIDOMIDE; TUMOR ANTIGEN; ANTINEOPLASTIC AGENT; CD20 ANTIGEN; DRUG DERIVATIVE; MONOCLONAL ANTIBODY;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENTIATION; HUMAN; HUMAN CELL; MONOCYTE; NATURAL KILLER CELL; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; BLOOD DISEASE; DRUG EFFECT; FLOW CYTOMETRY; IMMUNOLOGY; METABOLISM; WESTERN BLOTTING;

ANTIBODIES, MONOCLONAL; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTIGENS, CD20; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOTTING, WESTERN; FLOW CYTOMETRY; HEMATOLOGIC NEOPLASMS; HUMANS; KILLER CELLS, NATURAL; MONOCYTES; THALIDOMIDE;

EID: 51649123319     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-4405     Document Type: Article

References (22)

1. Leone G, Sica S, Voso MT, Rutella S, Pagano L. Treatment of acute leukaemias with monoclonal antibodies: current status and future prospects. Cardiovasc Hematol Agents Med Chem 2006;4:33-52.
2. Jazirehi AR, Bonavida B. Cellular and molecular signal transduction pathways modulated by rituximab (Rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention. Oncogene 2005;24: 2121-43.
3. Fischer L, Penack O, Gentilini C, et al. The antilymphoma effect of antibody-mediated immunotherapy is based on an increased degranulation of peripheral blood natural killer (NK) cells. Exp Hematol 2006;34:753-9.
4. Lieberman J. The ABCs of granule-mediated cytotoxicity: new weapons in the arsenal. Nat Rev Immunol 2003;3:361-70.
5. Dallegri F, Patrone F, Frumento G, Sacchetti C. Antibody-dependent killing of tumor cells by polymorphonuclear leukocytes. Involvement of oxidative and nonoxidative mechanisms. J Natl Cancer Inst 1984; 73:331-9.
6. Barker E. Reisfeld RA. A mechanism for neutrophilmediated lysis of human neuroblastoma cells Cancer Res 1993;53:362-7.
7. Mocchegiani E, Malavolta M. NK and NKT cell functions in immunosenescence. Aging Cell 2004;3 177-84.
8. List A, Dewald G, Bennett J. et al. Lenahdomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 2006;355:1456-65.
9. Dimopoulos MA, Spencer A, Attal M, et al. Study of lenalidomide plus dexamethasone versus dexamethasone alone in relapsed or refractory multiple myeloma (MM): results of a phase 3 study (MM-010) [abstract]. Blood 2005;106:6.
10. Weber D, Chen C, Niesvizky R, et al. Lenalidomide plus high-dose dexamethasone provides improved overall survival compared to high-dose dexamethasone alone for relapsed or refractory multiple myeloma (MM): results of a North American phase III study (MM-009) [abstract]. J Clin Oncol 2006;24:7521.
11. Wiernik PH, Lossos IS, Justice G, et al. Preliminary results from two phase II studies of lenalidomide monotherapy in relapsed/refractory non-Hodgkin's lymphoma [abstract]. J Clin Oncol 2006;24:17569.
12. Bartlett JB, Dredge K, Dalgleish AG. The evolution of thalidomide and its IMiD derivatives as anticancer agents. Nat Rev Cancer 2004;4:314-22.
13. Hernandez-llizaliturri FJ, Reddy N, Holkova B, Ottman E, Czuczman MS. Immunomodulatory drug CC-5013 or CC-4047 and rituximab enhance antitumor activity in a severe combined immunodeficient mouse lymphoma model. Clin Cancer Res 2005;11: 5984-92.
14. Tai YT, Li XF, Catley L, et al. Immunomodulatory drug lenalidomide (CC-5013, IMiD3) augments anti-CD40 SGN-40-induced cytotoxicity in human multiple myeloma: clinical implications. Cancer Res 2005;65: 11712-20.
15. Buske C, Dreyling M, Unterhalt M, Hiddemann W. Monoclonal antibody therapy for malignant lymphoma [in German; English abstract]. Med Klin (Munich) 2005;100:14-24.
16. Erratum in: Med Klin (Munich) 2005;100:346.
17. Marcus R, Hagenbeek A. The therapeutic use of rituximab in non-Hodgkin's lymphoma. Eur J Haematol 2007;78:5-14.
18. Davies FE, Raje N, Hideshima T, et al. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood 2001;98:210-6.
19. Trotta R, Puorro KA, Paroli M, et al. Dependence of both spontaneous and antibody-dependent, granule exocytosis-mediated NK cell cytotoxicity on extracellular signal-regulated kinases. J Immunol 1998;161: 6648-56.
20. Roda JM, Parihar R, Magro C, Nuovo GJ, Tridandapani S, Carson WE III. Natural killer cells produce T cell-recruiting chemokines in response to antibody-coated tumor cells. Cancer Res 2006;66: 517-26.
21. Brown CE, Vishwanath RP, Aguilar B, et al. Tumorderived chemokine MCP-1/CCL2 is sufficient for mediating tumor tropism of adoptively transferred T cells. J Immunol 2007;179:3332-41.
22. Bartlett JB, Michael A, Clarke IA, et al. Phase I study to determine the safety, tolerability and immunostimulatory activity of thalidomide analogue CC-5013 in patients with metastatic malignant melanoma and other advanced cancers. Br J Cancer 2004;90:955-61.